MEKi reduces sheddase activity via increased TIMP1 association, and TIMP1 neutralization enhances MAPKi efficacy. MEKi reduces sheddase activity via increased.

Slides:

Advertisements

Similar presentations

Neal et al.Supplementary Figure S1

Advertisements

Supplementary Figure 1: Clinical parameters of the breast tumor samples used for the study. IDC = Invasive ductal carcinoma and ILC= Invasive Lobular.

Expression of immune checkpoint molecules on leukocytes and tumor cells at baseline and in response to selinexor. Expression of immune checkpoint molecules.

A549 cells were transfected with the indicated plasmids

CDK4 is required for the hormone-independent growth of ER+ breast cancer cells. CDK4 is required for the hormone-independent growth of ER+ breast cancer.

Modulation of KRASG12C activity alters ARS-853 target engagement and supports novel therapeutic strategies for targeting KRAS. A, schematic for altering.

HDAC3, but not HDAC2 is in complex with tau protein.

DEAR1 binds to SMAD3 and induces SMAD3 ubiquitination.

FL cells are dependent on BCL6 in a NOTCH2-dependent manner.

Volume 136, Issue 4, Pages e3 (April 2009)

RAS/RAF pathway-activated ovarian cancer cells exhibit MEK dependence and synergistic induction of apoptosis with combined MEK/AKT inhibition. RAS/RAF.

Fig. 6. Increased efficacy of immunotherapy in lymphangiogenic B16 melanomas depends on CCR7 signaling before therapy and local activation and expansion.

APCFZR1 promotes BRAF ubiquitination in a D-box–dependent manner.

Molecular Therapy - Nucleic Acids

BRAFV600E promotes glycolysis in melanoma cells via regulation of GLUT1, GLUT3, and HK2. BRAFV600E promotes glycolysis in melanoma cells via regulation.

The PbGAPDH G6 fragment interacts with recombinant CD68.

PI(3,4,5)P3 releases SIN1-PH–mediated inhibition on mTOR-KD, leading to mTORC2 activation. PI(3,4,5)P3 releases SIN1-PH–mediated inhibition on mTOR-KD,

Signaling induced by BRAF L597R and L597S is sensitive to BRAF and MEK inhibitors. Signaling induced by BRAF L597R and L597S is sensitive to BRAF and MEK.

Overexpression of HGF decreases MET protein levels.

Role of HER2 in mediating acquired resistance to EGFR inhibition.

Effect of expression of constitutively active CAMKK2 on AMPK activation and the cell cycle in G361 cells. Effect of expression of constitutively active.

MEKi-induced RTK changes are consistent with decreased proteolytic receptor shedding. MEKi-induced RTK changes are consistent with decreased proteolytic.

CD8+ T cells were immunomodulated and required for the efficacy of anti–4-1BB/anti–PD-1 combination treatment. CD8+ T cells were immunomodulated and required.

Volume 18, Issue 3, Pages (March 2010)

by Kelly E. Johnson, Julia R. Ceglowski, Harvey G. Roweth, Jodi A

Volume 22, Issue 5, Pages (November 2012)

BRG1 interacts with RAD52 and regulates its accumulation at DSB sites during homologous recombination repair. BRG1 interacts with RAD52 and regulates its.

CD151-knockdown cells show an aberrant spreading response to PMA

Vps36 interacts with Smo in the absence of Hh

The contributions of anti-Ad antibody and T-cell responses to viral clearance in tumor and antitumor efficacy of Ad5 therapy. The contributions of anti-Ad.

Combined BRAFi and anti-CTLA4 administration leads to prolonged antitumor immunity in a patient with metastatic melanoma. Combined BRAFi and anti-CTLA4.

The role of p53 in H2O2-mediated cell death of hOGG1-deficient H1299 lung carcinoma p53 null cells. The role of p53 in H2O2-mediated cell death of hOGG1-deficient.

Overexpression of Pim kinases contributes to increased protein translation in resistant cells through controlling cap-independent translation. Overexpression.

Mitotic catastrophe symptoms caused by curcumin are followed by apoptosis. Mitotic catastrophe symptoms caused by curcumin are followed by apoptosis. A.

ST6GalNAc2 expression enhances tumor cells interaction with the vasculature. ST6GalNAc2 expression enhances tumor cells interaction with the vasculature.

CXCR4 expression levels of MDA-MB-231 cells at 48 hours posttransfection of CXCR4 siRNAs. CXCR4 expression levels of MDA-MB-231 cells at 48 hours posttransfection.

Overexpression of DDB2 reduces invasive abilities in lungs of aggressive breast tumor cells. Overexpression of DDB2 reduces invasive abilities in lungs.

Bcl-2 and caspase inhibition fails to inhibit BAMLET-induced cytotoxicity in MCF-7 cells. Bcl-2 and caspase inhibition fails to inhibit BAMLET-induced.

Ectopic expression of CA RSK1 mutant protects melanoma cells from PD98059-mediated apoptosis. Ectopic expression of CA RSK1 mutant protects melanoma cells.

CDN–treated MOC1 tumors demonstrate enhanced activation of innate and antigen-specific adaptive immunity. CDN–treated MOC1 tumors demonstrate enhanced.

ARID1A promotes DSB end resection.

Binding and antiproliferative effects of ANG4043 and anti-HER2 mAbs on tumor cells. Binding and antiproliferative effects of ANG4043 and anti-HER2 mAbs.

Synergistic cytotoxicity of 17AAG and TNF treatment in human lung cancer cell lines. Synergistic cytotoxicity of 17AAG and TNF treatment in human lung.

Dual blockade of PD-1 and CTLA-4 directly activates CD4+Foxp3− cells in the absence of CD8+ or CD4+Foxp3+ cells. Dual blockade of PD-1 and CTLA-4 directly.

TET2 interacts with KLF1 transcription factor.

Immunologic and pharmacokinetic studies.

Ketogenic diets combined with fractionated radiation treatment results in decreased immunoreactive PCNA in tumor tissue. Ketogenic diets combined with.

RUNX3 depletion induces cellular senescence and inflammatory cytokine expression in cells undergoing TGFβ-mediated EMT. A, Cells were transfected with.

HMQ1611 inhibited breast tumor growth in mice.

Met is expressed in Her2-overexpressing cell lines and Her2 (+) breast tumors. Met is expressed in Her2-overexpressing cell lines and Her2 (+) breast tumors.

Tumor protection induced by therapeutic PLG vaccination in combination with blockade antibodies. Tumor protection induced by therapeutic PLG vaccination.

Trametinib and combination promote moDC maturation and decrease moDC viability. Trametinib and combination promote moDC maturation and decrease moDC viability.

The PI3Kβ inhibitor enhances the antitumor activity of T cell–mediated immunotherapy in mice bearing PTEN loss tumors. The PI3Kβ inhibitor enhances the.

Amino acid residues in the PD-L1 IgV domain involved in PD-1 and/or B7-1 binding. Amino acid residues in the PD-L1 IgV domain involved in PD-1 and/or B7-1.

Induction of PARP cleavage (A) and activation of caspases (B) after treatment with a combination of TRAIL and cisplatin. Induction of PARP cleavage (A)

αvβ6 functional assays in the β cell line using blocking antibodies.

Effect of MIF siRNA on the production of MMP-13 induced by LPA

PARP1 suppresses the transcription of PD-L1 in cancer cells.

NEDD9 binding to AURKA decreases the efficacy of AURKA inhibitors in vitro. NEDD9 binding to AURKA decreases the efficacy of AURKA inhibitors in vitro.

MPD-L1–transfected 300 cells do not bind to mB7-1–transfected 300 cells. mPD-L1–transfected 300 cells do not bind to mB7-1–transfected 300 cells. Cell-to-cell.

THZ1 in combination with targeted therapy enhances cell death and hinders the establishment of drug-resistant colonies in diverse oncogene-addicted cellular.

Ex vivo profiling of PD-1 blockade using MDOTS

IL2Cx alone or in combination with anti–CTLA-4 increases the CD8/Treg ratio in the tumor. IL2Cx alone or in combination with anti–CTLA-4 increases the.

Curcumin decreases viability and proliferation of Bcr-Abl-expressing cells. Curcumin decreases viability and proliferation of Bcr-Abl-expressing cells.

TAMs upregulate DNMT1 in gastric cancer cells through the CCL5/CCR5/STAT3 pathway. TAMs upregulate DNMT1 in gastric cancer cells through the CCL5/CCR5/STAT3.

I3C reduces the level of Cdc25A protein in breast cancer cells.

Knockdown of ROR1 increases the invasive potential of melanoma cells in vitro and in vivo. Knockdown of ROR1 increases the invasive potential of melanoma.

DQs have superior anticancer efficacy among dimeric antimalarials.

Fig. 2. Cellular response to FolamiRs in vitro.

Trametinib and combination decrease T-lymphocyte proliferation.

Presentation transcript:

MEKi reduces sheddase activity via increased TIMP1 association, and TIMP1 neutralization enhances MAPKi efficacy. MEKi reduces sheddase activity via increased TIMP1 association, and TIMP1 neutralization enhances MAPKi efficacy. A, MEKi reduces ADAM10 and ADAM17 catalytic activities in MDA-MB-231, directly measured using the live-cell PrAMA assay (*, P < 0.05; n= 4). B, live-cell immunostaining shows knockdown of TIMP1, but not TIMP3, reduces surface AXL in MDA-MB-231, 24 hours after PD325901 treatment and 72 hours after transfection (*, P < 0.05; n= 3; knockdown validation: Supplementary Fig. S7D). C, cotreatment with a TIMP1 neutralization antibody (T1-NAB) blocks tumor AXL accumulation following BRAFi/MEKi treatment in the LOX-IMVI melanoma xenograft model, shown by immunofluorescence quantification (*, P= 0.02; n≥ 2). D, live-cell immunostaining shows MEKi increases surface TIMP1 in MDA-MB-231. E, flow cytometry shows 5-minute MEKi treatment increases rTIMP1-fluor binding to the cell surface (*, P < 0.05; n= 4). F, significant co-IP of ADAM10-HA and rTIMP-fluor is only detected in bulk anti-HA IP lysate from cells transfected with ADAM10-HA and treated with U0126 (*, P < 0.05; n= 3; pooled two-tailed t test). G and H, the 120-kDa ADAM10 dimerization band (39) and co-IP with rTIMP1 increases with 5-minute MEKi (*, P < 0.05; n > 3). I, pretreatment (24 hours) with a TIMP1 neutralization antibody (T1-NAB) followed by cotreatment with PD325901 (MEKi) or vemurafenib (BRAFi) leads to enhanced reduction in cell count at 72 hours, normalized to the effect size of BRAFi or MEKi alone (*, P= 0.03, pooled two-tailed t test, n= 18 total reps). J and K, T1-NAB cotreatment synergistically increases BRAFi/MEKi efficacy in the LOX-IMVI xenograft model by enhancing initial tumor shrinkage (J; P= 0.014, two-way ANOVA interaction term, total n= 46) and delaying tumor recurrence (K; P= 0.04, two-tailed t test, n≥ 8 per group). L, overview schematic of RTK shedding as a mechanism of MAPKi resistance. Miles A. Miller et al. Cancer Discov 2016;6:382-399 ©2016 by American Association for Cancer Research